Image of fictitious patient

Long-term fatigue

ZEJULA has a comparable fatigue burden over 30 cycles of maintenance therapy vs placebo, as observed in PRIMA1*

*Statistical significance not assessed.

Patient-reported burden of fatigue in PRIMA during treatment (data cut-off: primary analysis):1†

A graph showing long-term fatigue in overall population for Zejula (Niraparib) vs Placebo

Figure adapted from Halla K, et al. 2020.
Exploratory analysis, results should be interpreted with caution.

ZEJULA (niraparib) is indicated2

  • as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
  • as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Abbreviations

EORTC-QLQ-C30, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire; FIGO, Federation of Gynaecology and Obstetrics; SD, standard deviation.

References

  1. Halla K, et al. Poster presented at the Oncology Nursing Society 45th Annual Congress, 29 April–3 May, 2020, San Antonio, TX.
  2. Zejula (niraparib) Summary of product characteristics (Last Accessed: April 2024).

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk (UK) or search for MHRA Yellow Card in the Google Play or Apple App store. Adverse events should also be reported to GSK Limited on 0800 221 441 or by email at uksafety@gsk.com.

©2024 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.

April 2024 | PM-GB-NRP-WCNT-220020 (V2.0)